| Quantity: | |
|---|---|
Broad model portfolio – Covers T cell-dependent, B cell-dependent, relapsing-remitting, chronic progressive, and secondary progressive MS subtypes.
Multiple species/strains – C57BL/6, SJL/J, Lewis rat, and specialized strains available.
Comprehensive endpoints – Body weight, clinical score, CNS cellular infiltration (flow cytometry), molecular profiling (cytokines, autoantibodies), histopathology (HE, Luxol fast blue), B cell/T cell phenotyping.
Translational value – Ideal for testing immunomodulators (fingolimod, natalizumab, ocrelizumab), remyelinating agents, and neuroprotective therapies.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
MOG35-55 Induced T cell dependent EAE Model
MOG1-125 Induced B cell dependent EAE Model
MOG induced NOD SP-MS Model
PLP induced SJL/J RR-MS Model
MBP68-86 induced EAE Model in Lewis Rats
• Efficacy testing of immunomodulators (fingolimod, dimethyl fumarate, teriflunomide, cladribine)
• Evaluation of biologics (natalizumab, ocrelizumab, ofatumumab, alemtuzumab) targeting T cells, B cells, or adhesion molecules
• Testing of remyelinating and neuroprotective agents
• Target validation for Th1/Th17, B cell, and antigen presentation pathways
• IND-enabling pharmacology and toxicology studies
Parameter | MOG35-55 T cell EAE | PLP RR-MS Model | SP-MS Mouse Model | MOG1-125 B cell EAE | Lewis Rat EAE |
Species/Strain | C57BL/6 mouse | SJL/J mouse | Mouse (various) | C57BL/6 mouse | Lewis rat |
Induction method | MOG35-55 + CFA + PTx | PLP139-151 + CFA + PTx | Chronic antigen or transgenic | MOG1-125 + CFA | MBP68-86 + CFA |
Key endpoints | Chronic progressive | Relapsing-remitting | Secondary progressive | Chronic (B cell mediated) | Acute monophasic |
Data package | Body weight, clinical score, CNS cellular infiltration, cytokine/autoantibody levels, spinal cord histopathology (HE & LFB), optional: B cell phenotyping, T cell assays | ||||
Q: What are the differences between CIA models in different strains?
A: DBA/1 mice are the most susceptible strain with high incidence and severe arthritis. C57BL/6 mice develop moderate arthritis with more variable onset, useful for genetic modifications. Wistar rats provide larger joint size for histopathology and imaging, and are preferred for certain pharmacokinetic studies.
Q: Which model is best for testing biologics?
A: All three models are suitable. DBA/1 mice are traditionally used for anti-TNF and anti-IL-6R studies due to high disease penetrance. C57BL/6 mice allow use of knockout/transgenic strains. Rats offer advantages for serial blood sampling and imaging.
Q: Can these models be used for IND-enabling studies?
A: Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different collagen doses, booster timing, combination therapies)?
A: Absolutely. Our scientific team tailors immunization protocols, treatment schedules, and endpoint analyses to your specific drug candidate.
